ERBB3 and lung cancer: In ALK‐rearranged lung cancer, it has been reported that HER3 activation contributes to maintaining cell survival while inducing ALK‐TKI‐DTC occurrence, whereas the treatment with afatinib, a pan‐HER inhibitor, combined with ALK‐TKIs could suppress tumor growth and eventually eliminate DTCs.228